Ignite Creation Date:
2024-05-05 @ 11:27 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00048217
Status:
UNKNOWN
Last Update Posted:
2005-06-24
First Post:
2002-10-28
Brief Title:
A Rollover Study to Provide Chronic T-1249 to Patients Who Completed Study T1249-102
Sponsor:
Trimeris
Organization:
Trimeris
Study Overview
Official Title:
None
Status:
UNKNOWN
Status Verified Date:
2004-07
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Patients who complete study T1249-102 must be currently failing a T-20 containing regimen to participate in this study will receive T-1249 at a dose of 200mg daily in combination with a background antiretroviral regimen for 96 weeks Only patients that participated in study T1249-102 can participate in study T1249-105
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None